Tetanus vaccine - Zydus Lifesciences
Latest Information Update: 28 Sep 2024
At a glance
- Originator Cadila Healthcare
- Developer Zydus Lifesciences
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Tetanus
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for phase-I development in Tetanus(In adolescents, Prevention, In adults) in India (IM)
- 21 Aug 2017 Cadila Healthcare completes a phase II/III trial in Tetanus (In volunteers, In children, In adolescents, In adults) in India (IM) (CTRI2015-05-005740)
- 21 Feb 2014 Phase-I clinical trials in Tetanus (In adolescents, In adults, Prevention) in India (IM) (CTRI2014-01-004358)